Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Takeda Pharmaceutical Co Ltd | 1,201 |
| 2 | Pfizer Inc | 279 |
| 3 | Kissei Pharmaceutical Co Ltd | 168 |
| 4 | AbbVie Inc | 109 |
| 5 | Merck KGaA | 97 |
| 6 | C.H. Boehringer Sohn AG and Co KG | 72 |
| 7 | Structure Therapeutics Inc | 58 |
| 8 | Sumitomo Chemical Co Ltd | 58 |
| 9 | Harvard University | 49 |
| 10 | The University of Texas System | 47 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 3,903 |
| 2 | A61K | Medicinal preparations | 3,301 |
| 3 | C07D | Heterocyclic compounds | 2,219 |
| 4 | C07C | Acyclic and carbocyclic compounds | 484 |
| 5 | C07H | Sugars and derivatives | 382 |
| 6 | C07K | Peptides | 322 |
| 7 | C12N | Microorganisms, enzymes | 199 |
| 8 | C07F | Organometallic compounds | 171 |
| 9 | Y02A | Climate change adaptation | 167 |
| 10 | G01N | Investigating / analysing materials | 155 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Tolrestat or a salt thereof as an immuno-stimulating agent | 1988 | Pfizer Inc | 6 |
| Tolrestat for hearing impairment | 1988 | Pfizer Inc | 5 |
| Prodn. of methyl 5-bromo-6-methoxy-1-naphthoate - used as tolrestat intermediate, comprises reaction of methyl 6-methoxy-1-naphthoate with bromine in presence of oxidising agent | 1994 | Sanofi SA | 2 |
| Tolrestat for wound healing | 1988 | Pfizer Inc | 1 |
| STABILIZED TOLRESTAT ROTATION ISOMER COMPOSITION | 1986 | Pfizer Inc | 1 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2023 | 2 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Aruni Bhatnagar | University of Louisville | 22 |
| 2 | Sanjay Srivastava | University of Louisville | 12 |
| 3 | Kota V. Ramana | The University of Texas Medical Branch at Galveston | 12 |
| 4 | Satoshi Endo | Gifu Pharmaceutical University | 11 |
| 5 | Ossama El‐Kabbani | Monash University | 11 |
| 6 | D. Dvornik | Princeton University | 11 |
| 7 | Akira Hara | Gifu Pharmaceutical University | 10 |
| 8 | Satish K. Srivastava | The University of Texas Medical Branch at Galveston | 10 |
| 9 | Jane Millen | University of North Carolina at Chapel Hill | 9 |
| 10 | Joseph R. Williamson | Washington University in St. Louis | 7 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Role of Aldose Reductase and Oxidative Damage in Diabetes and the Consequent Potential for Therapeutic Options | 2005 | 527 | Heme Oxygenase-1 and Carbon Monoxide |
| Elevated Triglycerides Correlate With Progression of Diabetic Neuropathy | 2009 | 348 | Pain Mechanisms and Treatments |
| PocketPicker: analysis of ligand binding-sites with shape descriptors | 2007 | 345 | Protein Structure and Dynamics |
| Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones | 2002 | 256 | Alcohol Consumption and Health Effects |
| Soft Docking and Multiple Receptor Conformations in Virtual Screening | 2004 | 237 | Computational Drug Discovery Methods |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition and weight of Tolrestat?
Which organizations hold the most patents related to Tolrestat?
What are some notable historical patents on Tolrestat and their stated applications?
What research topics are most frequently associated with Tolrestat in the patent literature?
Who are the most prolific authors in Tolrestat research literature?